Gingerly, startups take a virtual approach

The Wall Street Journal has found that the new generation of biotech startups are wrapping their business models around virtual space to scale back on costs but still keep research goals high. For the startup, the model's quite simple: Focus on one asset and pad the cost of failure. For investors, it's just as simple: Invest no more than $2 million or $3 million in the startup's first year, and expect either a lofty return or no harm done. Of course, the obvious pitfall is that contractors may not see eye-to-eye with their clients on a project. Story (sub. req.) | More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.